BCL2 and breast carcinoma: Vorinostat, an HDACi, along with TRAIL increased anoikis by causing dissipation of mitochondrial membrane potential, activation of caspase-3 and reduction of phosphorylation of BCL-2 family protein in breast cancer cells [186].